vs
信安金融集团（PFG）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是信安金融集团的1.0倍（$772.1M vs $750.8M），Revvity净利率更高（12.7% vs 0.3%，领先12.5%），Revvity同比增速更快（5.9% vs 4.0%），过去两年Revvity的营收复合增速更高（9.0% vs -58.3%）
信安金融集团（股票代码：PFG）是总部位于美国艾奥瓦州得梅因的全球性金融服务企业，核心业务涵盖投资管理、保险服务两大板块，在全球多个区域开展业务，为机构客户和个人用户提供专业定制化的金融解决方案，在行业内拥有较高知名度。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PFG vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.0倍
$750.8M
营收增速更快
RVTY
高出1.9%
4.0%
净利率更高
RVTY
高出12.5%
0.3%
两年增速更快
RVTY
近两年复合增速
-58.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $750.8M | $772.1M |
| 净利润 | $1.9M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 0.3% | 12.7% |
| 营收同比 | 4.0% | 5.9% |
| 净利润同比 | 783.0% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PFGRVTY
| Q1 26 | $750.8M | — | ||
| Q4 25 | $4.6B | $772.1M | ||
| Q3 25 | $3.7B | $698.9M | ||
| Q2 25 | $3.7B | $720.3M | ||
| Q1 25 | $3.7B | $664.8M | ||
| Q4 24 | $4.8B | $729.4M | ||
| Q3 24 | $3.0B | $684.0M | ||
| Q2 24 | $4.3B | $691.7M |
净利润PFGRVTY
| Q1 26 | $1.9M | — | ||
| Q4 25 | $517.0M | $98.4M | ||
| Q3 25 | $213.8M | $46.7M | ||
| Q2 25 | $406.2M | $53.9M | ||
| Q1 25 | $48.1M | $42.2M | ||
| Q4 24 | $905.4M | $94.6M | ||
| Q3 24 | $-220.0M | $94.4M | ||
| Q2 24 | $353.1M | $55.4M |
毛利率PFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率PFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | — | 12.4% |
净利率PFGRVTY
| Q1 26 | 0.3% | — | ||
| Q4 25 | 11.3% | 12.7% | ||
| Q3 25 | 5.8% | 6.7% | ||
| Q2 25 | 11.1% | 7.5% | ||
| Q1 25 | 1.3% | 6.4% | ||
| Q4 24 | 19.1% | 13.0% | ||
| Q3 24 | -7.3% | 13.8% | ||
| Q2 24 | 8.2% | 8.0% |
每股收益（稀释后）PFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | $2.30 | $0.86 | ||
| Q3 25 | $0.95 | $0.40 | ||
| Q2 25 | $1.79 | $0.46 | ||
| Q1 25 | $0.21 | $0.35 | ||
| Q4 24 | $3.92 | $0.77 | ||
| Q3 24 | $-0.95 | $0.77 | ||
| Q2 24 | $1.49 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | — | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | $4.4B | $919.9M | ||
| Q3 25 | $5.1B | $931.4M | ||
| Q2 25 | $3.7B | $991.8M | ||
| Q1 25 | $3.9B | $1.1B | ||
| Q4 24 | $4.2B | $1.2B | ||
| Q3 24 | $6.2B | $1.2B | ||
| Q2 24 | $4.8B | $2.0B |
总债务PFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | $3.9B | — | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $3.9B | — | ||
| Q1 25 | $4.3B | — | ||
| Q4 24 | $4.0B | — | ||
| Q3 24 | $3.9B | — | ||
| Q2 24 | $3.9B | — |
股东权益PFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | $11.9B | $7.3B | ||
| Q3 25 | $11.7B | $7.4B | ||
| Q2 25 | $11.4B | $7.6B | ||
| Q1 25 | $11.2B | $7.6B | ||
| Q4 24 | $11.1B | $7.7B | ||
| Q3 24 | $11.2B | $7.9B | ||
| Q2 24 | $11.0B | $7.9B |
总资产PFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | $341.4B | $12.2B | ||
| Q3 25 | $334.5B | $12.1B | ||
| Q2 25 | $323.1B | $12.4B | ||
| Q1 25 | $313.0B | $12.4B | ||
| Q4 24 | $313.7B | $12.4B | ||
| Q3 24 | $322.9B | $12.8B | ||
| Q2 24 | $308.8B | $13.4B |
负债/权益比PFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.33× | — | ||
| Q3 25 | 0.34× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.39× | — | ||
| Q4 24 | 0.36× | — | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | 0.36× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流PFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.7B | $182.0M | ||
| Q3 25 | $1.0B | $138.5M | ||
| Q2 25 | $811.9M | $134.3M | ||
| Q1 25 | $977.3M | $128.2M | ||
| Q4 24 | $1.5B | $174.2M | ||
| Q3 24 | $1.1B | $147.9M | ||
| Q2 24 | $1.4B | $158.6M |
自由现金流PFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M |
自由现金流率PFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% |
资本支出强度PFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% |
现金转化率PFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | 3.37× | 1.85× | ||
| Q3 25 | 4.70× | 2.97× | ||
| Q2 25 | 2.00× | 2.49× | ||
| Q1 25 | 20.32× | 3.03× | ||
| Q4 24 | 1.61× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 4.05× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PFG
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
